Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Pfizer and BioNTech to offer COVID-19 vaccine to placebo recipients  

By Brian Buntz | January 5, 2021

COVID-19 therapies vaccines coronavirus

[Photo by Daniel Schludi on Unsplash]

Pfizer (NYSE:PFE) and BioNTech (NSDQ:BNTX) have decided to offer to inform clinical trial volunteers in its COVID-19 vaccine whether they received a vaccine or placebo. Those who received a placebo will be eligible to receive the first dose of vaccine by March 1 and stay in the study. A second dose will be administered roughly three weeks after the first dose. 

Roughly half of the 44,000-plus participants in the BNT162b2 vaccine trial received a placebo. 

The question of whether to vaccinate placebo recipients in COVID-19 vaccine studies is difficult to answer. “We face this in every clinical trial, particularly on data monitoring committees,” said Dr. Steven Goodman, professor of epidemiology at Stanford University, in an FDA advisory meeting for the Pfizer-BioNTech vaccine on Dec. 10. “There is tension between actions that are good for an individual, which in the current setting might mean giving them a vaccine immediately, and what’s best for society, which might mean holding off on that vaccine so placebo controlled randomized trials can continue,” he said. 

Before their vaccine won emergency use authorization, Pfizer and BioNTech informed the FDA that they would plan to offer vaccination to placebo recipients 16 years of age and older.

Pharmaceutical companies are not obligated to provide immediate vaccination to participants in COVID-19 vaccine trials, Goodman said. Several groups, including the CDC, have devised prioritization criteria to identify the optimal schedule of mass vaccination. “And I haven’t seen one that includes trial participation as a basis for jumping the queue,” Goodman said. “That is not considered a reason to get it before somebody else who might deserve it or need it because of higher risk or other consideration. “

 


Filed Under: clinical trials, Drug Discovery, Infectious Disease, Uncategorized
Tagged With: BioNTech, coronavirus, covid-19, COVID-19 vaccine, Pfizer
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Pfizer
Pfizer shares positive top-line data from Phase 3 Study of pneumococcal vaccine
Vaccine
The most common monkeypox vaccine side effects
FDA logo
FDA grants emergency use authorization to Jynneos monkeypox vaccine to support ‘dose sparing’
JYNNEOS vaccine
Jynneos vaccine: The best weapon against monkeypox?

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50